中國寶力科技(00164.HK)與第三方合作改良技術
中國寶力科技(00164.HK)公布,昨日(23日)與華盈礦山、卓能環球及國通集團訂立認購協議及股東協議,公司將與這三方合作集團成立合作公司,將公司的伽瑪射線技術及專有知識,整合至華盈礦山的乾磨乾選技術中。
認購完成後,公司將擁有合作公司51%的權益,華盈礦山擁有30%的權益及卓能集團擁有19%,合作公司及其附屬公司將成為公司非全資附屬公司,其財務業績將綜合入賬至集團財務報表。
公司指,通過該合作,經改良的技術將成為鐵礦山規劃及設計取得重大突破的基石,其提供金屬鐵礦石的勘探、選礦、研磨及生產的實時評估,這將極大提高精礦及礦團中的總鐵含量,同時亦滿足地質、經濟及環境方面的參數。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.